15.01.2020 • News

American Vanguard Buys Corteva Herbicides

Corteva Agriscience has agreed to take over J.G. Bosell’s stake in their...
Corteva Agriscience has agreed to take over J.G. Bosell’s stake in their joint-venture company PhytoGen Seed Co. Owning a 53.5% stake. Corteva has operated the jv in the US market through wholly owned subsidiary Mycogen. Financial terms were not disclosed. (c) Corteva

US specialty agricultural products company American Vanguard has bought four herbicide brands from Corteva Agriscience, namely Classic, First Rate, Hornet and Python.

American Vanguard said the brands are complementary tank-mix partners for a variety of primary herbicides used in the US and are particularly valuable for enhancing weed control performance against increasing numbers of resistant weed species.

Eric Wintemute, American Vanguard’s chairman and CEO, added that the brands broaden the company’s US herbicide offering in soybeans, corn, peanuts and a number of other niche crop markets.  

He commented: “These brands have well-established market positions, are solidly profitable and can be readily incorporated into our existing sales and marketing programs. We are very excited about the opportunity these products provide in helping our valued customers improve crop yields through superior weed control management in a number of crop segments that are strategically important to drive American Vanguard’s growth.”

The transaction includes end-use registrations, commercial sales and marketing information and finished goods inventory. Financial terms were not revealed.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read